The cuts are expected to take effect by Nov. 28 and will happen across several departments at the biotech drug manufacturer.
According to its website, Genentech is “dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.”
In a statement sent to KRON4 News, Genentech addressed the WARN filing. “We consistently evaluate all facets of our operations to ensure we remain well-positioned to meet patients’ evolving needs today while continuing to deliver innovative new medicines in the future. This means that, periodically, adjustments and decisions are necessary regarding the makeup of our workforce across our company’s various functions. As part of these ongoing evaluations, we identified the need to reduce 118 positions across several departments.”
Discover more from RSS Feeds Cloud
Subscribe to get the latest posts sent to your email.
